Literature DB >> 18544228

Markers of oxidative damage in chronic heart failure: role in disease progression.

Slavica Radovanovic1, Mirjana Krotin, Dragan V Simic, Jasmina Mimic-Oka, Ana Savic-Radojevic, Marija Pljesa-Ercegovac, Marija Matic, Nebojsa Ninkovic, Branislava Ivanovic, Tatjana Simic.   

Abstract

BACKGROUND: We aimed to study the relationship between markers of oxidative lipid or protein damage and ventricular remodeling and the validity of 8-epi-prostaglandin F(2alpha) (8-epi-PGF(2alpha)) as an indicator of disease severity in patients with ischemic chronic heart failure (CHF). PATIENTS AND METHODS: We enrolled four groups of 12 patients with varying CHF according to the New York Heart Association (NYHA) classification and 25 controls. Urinary 8-epi-PGF(2alpha) and plasma malondialdehyde and protein thiol (P-SH) groups were correlated with echocardiographic indices of remodeling. The reliability of isoprostanes was analyzed by a receiver operating characteristics (ROC) curve.
RESULTS: NYHA class III and IV patients exhibited elevated 8-epi-PGF(2alpha) levels, increased malondialdehyde concentrations and decreased P-SH groups when compared to controls and NYHA I and II patients. 8-Epi-PGF(2alpha) and P-SH groups correlated significantly with indices of remodeling. The ROC curve drawn for 8-epi-PGF(2alpha) allowed us to differentiate NYHA class III and IV patients from NYHA class I and II patients with a sensitivity of 95.8% and specificity of 95.8% (cut off 0.84 ng/mg creatinine; area under curve 0.99; P < 0.001).
CONCLUSIONS: Markers of oxidative damage are unlikely to play a significant role in early stages of CHF. However, they might become important in the course of CHF when their concentrations reach critical levels. Urinary 8-epi-PGF(2alpha) is a reliable indicator of symptomatic CHF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544228     DOI: 10.1179/135100008X259204

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  7 in total

Review 1.  The contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failure.

Authors:  Pamela Harding; David B Murray
Journal:  Life Sci       Date:  2011-08-10       Impact factor: 5.037

Review 2.  Novel Biomarkers of Heart Failure in Pediatrics.

Authors:  Teja Senekovič Kojc; Nataša Marčun Varda
Journal:  Children (Basel)       Date:  2022-05-18

3.  Cardiac-specific overexpression of catalase identifies hydrogen peroxide-dependent and -independent phases of myocardial remodeling and prevents the progression to overt heart failure in G(alpha)q-overexpressing transgenic mice.

Authors:  Fuzhong Qin; Shannon Lennon-Edwards; Steve Lancel; Andreia Biolo; Deborah A Siwik; David R Pimentel; Gerald W Dorn; Y James Kang; Wilson S Colucci
Journal:  Circ Heart Fail       Date:  2009-12-16       Impact factor: 8.790

4.  Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts.

Authors:  Jason D Gardner; David B Murray; Tetyana G Voloshenyuk; Gregory L Brower; Jessica M Bradley; Joseph S Janicki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-20       Impact factor: 4.733

Review 5.  Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation.

Authors:  Jochen Bauer; Anne Ripperger; Stefan Frantz; Süleyman Ergün; Edzard Schwedhelm; Ralf A Benndorf
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

6.  Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis.

Authors:  Thomas J van 't Erve; Maria B Kadiiska; Stephanie J London; Ronald P Mason
Journal:  Redox Biol       Date:  2017-03-28       Impact factor: 11.799

7.  Comparison of Oxidative Stress Parameters in Heart Failure Patients Depending on Ischaemic or Nonischaemic Aetiology.

Authors:  Ewa Romuk; Celina Wojciechowska; Wojciech Jacheć; Jolanta Nowak; Jacek Niedziela; Jolanta Malinowska-Borowska; Anna Głogowska-Gruszka; Ewa Birkner; Piotr Rozentryt
Journal:  Oxid Med Cell Longev       Date:  2019-09-17       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.